Nuclease Immune Mediated Brain and Lupus-like conditions (NIMBL): natural history, pathophysiology, diagnostic and therapeutic modalities with application to other disorders of autoimmunity

In the NIMBL project, clinicians and research scientists have united to share their knowledge and expertise and increase the number of people in the study to benefit all affected families, both now and in the future.

The NIMBL research study aims to gain a greater understanding of:

  • the normal progress of these illnesses, including the biochemical changes
  • the underlying cause (genetic and biochemical)

This should help to:

  • give an earlier, faster and more accurate diagnosis in the future
  • suggest and investigate potential new treatments and therapies
  • provide insight into other autoimmune conditions (e.g. systemic lupus erythematosus)

The investigation of NIMBL diseases will not only improve the health and well-being of NIMBL patients and their families, it is also expected to lead to better treatments of much more common autoimmune disorders including lupus.

Short name and number: 
NIMBL, 241779
Name of US Partner: 
UNIVERSITY OF WASHINGTON; CHILDREN'S RESEARCH INSTITUTE (CRI)
Contact: 

UNIVERSITY OF WASHINGTON

Administrative contact: Lynne CHRONISTER (Ms.)
BROOKLYN AVENUE NE 4333, 359472, SEATTLE WA, UNITED STATES
Tel: +1-2065436633
Fax: +1-2066851732

CHILDREN'S RESEARCH INSTITUTE (CRI)

Administrative contact: Monique FOXX (Ms.)
Michigan Avenue 111, WASHINGTON, DC, UNITED STATES
Tel: +30-1-5658483
Fax: +30-1-5658474

Participating Countries: 
Italy
Spain
The Netherlands
United Kingdom
United States
Area: 

Health

Category: 

FP7 Project with U.S. partner